FindTrial
Sign In

This is a study will be done to study the efficacy and adverse effects of phototherapy in vitiligo patients and also to compare the efficacy and adverse effects of laser plus phototherapy versus phototherapy alone in vitiligo patients.

COMBINATION OF FRACTIONAL CO2 LASER AND NARROW BAND ULTRAVIOLET-B PHOTOTHERAPY VERSUS NARROW BAND ULTRAVIOLET-B PHOTOTHERAPY ALONE IN VITILIGO PATIENTS:A COMPARATIVE STUDY

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031149
Enrollment
30
Registered
2021-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Fractional CO2 laser: Fractional CO2 Laser of Derma India Company will be used. Control Intervention1: Whole body NB- UVB phototherapy: NB-UVB phototherapy of V Care Company, Philip TL

Sponsors

GSL MEDICAL COLLEGE AND GENERAL HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 â?? 65 years having symmetrical stable vitiligo lesions. 2. Vitiligo patients with symmetrical stable lesions who will give consent for Fractional CO2 laser procedure and NB UVB Therapy will be included in the study

Exclusion criteria

Exclusion criteria: 1. Infection over lesional sites. 2. Pregnant and breastfeeding women. 3. Patients with history of skin cancer, keloid, hypertrophic scar, photosensitivity disorders and koebnerâ??s phenomenon will be excluded.

Design outcomes

Primary

MeasureTime frame
This study will reveal whether combining Fractional CO2 laser and Narrow Band Ultraviolet B phototherapy will be a better safer and efficient method than Narrow Band Ultraviolet B phototherapy alone in vitiligo lesions.Timepoint: 18 months—

Secondary

MeasureTime frame
Combination of Fractional CO2 Laser and NB-UVB Phototherapy could be added as new emerging modality of treatment for vitiligo lesions.Timepoint: 18 months—

Countries

India

Contacts

Public ContactBALA VAISHNAVI LINGAMANENI

HOD IN GSL MEDICAL COLLEGE AND GENERAL HOSPITAL

arumilliskin@gmail.com9246655555

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026